Blanchard Z, Brown E, Ghazaryan A, Welm A
Nat Rev Cancer. 2024; 25(3):153-166.
PMID: 39681638
DOI: 10.1038/s41568-024-00779-3.
Wang E, Xiang K, Zhang Y, Wang X
J Natl Cancer Cent. 2024; 2(4):263-276.
PMID: 39036550
PMC: 11256726.
DOI: 10.1016/j.jncc.2022.10.001.
Philp L
Methods Mol Biol. 2024; 2806:153-185.
PMID: 38676802
DOI: 10.1007/978-1-0716-3858-3_12.
Stevens A, Terrell M, Rashid R, Fisher K, Marcogliese A, Gaikwad A
Biomedicines. 2024; 12(2).
PMID: 38397996
PMC: 10886789.
DOI: 10.3390/biomedicines12020394.
Hernandez Guerrero T, Banos N, Del Puerto Nevado L, Mahillo-Fernandez I, Doger De-Speville B, Calvo E
Cancers (Basel). 2023; 15(22).
PMID: 38001663
PMC: 10670531.
DOI: 10.3390/cancers15225402.
Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.
Hampton J, Peterson E, Katner S, Turner T, Alzubi M, Harrell J
Mol Cancer Ther. 2021; 21(2):271-281.
PMID: 34815360
PMC: 8828673.
DOI: 10.1158/1535-7163.MCT-20-0969.
Current Status and Perspectives of Patient-Derived Models for Ewing's Sarcoma.
Kondo T
Cancers (Basel). 2020; 12(9).
PMID: 32899796
PMC: 7563399.
DOI: 10.3390/cancers12092520.
Current status and perspectives of patient-derived rare cancer models.
Kondo T
Hum Cell. 2020; 33(4):919-929.
PMID: 32537685
DOI: 10.1007/s13577-020-00391-1.
Identification of synergistic drug combinations using breast cancer patient-derived xenografts.
Turner T, Alzubi M, Harrell J
Sci Rep. 2020; 10(1):1493.
PMID: 32001757
PMC: 6992640.
DOI: 10.1038/s41598-020-58438-0.
Generation and application of patient-derived xenograft models in pancreatic cancer research.
Wang C, Shi X
Chin Med J (Engl). 2019; 132(22):2729-2736.
PMID: 31725451
PMC: 6940092.
DOI: 10.1097/CM9.0000000000000524.
A Melanoma Patient-Derived Xenograft Model.
Xiao M, Rebecca V, Herlyn M
J Vis Exp. 2019; (147).
PMID: 31157772
PMC: 6986799.
DOI: 10.3791/59508.
Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development.
Schueler J, Klingner K, Bug D, Zoeller C, Maier A, Dong M
Oncotarget. 2018; 9(57):30946-30961.
PMID: 30123419
PMC: 6089561.
DOI: 10.18632/oncotarget.25697.
Addressing the challenges of applying precision oncology.
Shin S, Bode A, Dong Z
NPJ Precis Oncol. 2018; 1(1):28.
PMID: 29872710
PMC: 5871855.
DOI: 10.1038/s41698-017-0032-z.
Animal models of cholangiocarcinoma.
Loeuillard E, Fischbach S, Gores G, Ilyas S
Biochim Biophys Acta Mol Basis Dis. 2018; 1865(5):982-992.
PMID: 29627364
PMC: 6177316.
DOI: 10.1016/j.bbadis.2018.03.026.
Management and potentialities of primary cancer cultures in preclinical and translational studies.
Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F
J Transl Med. 2017; 15(1):229.
PMID: 29116016
PMC: 5688825.
DOI: 10.1186/s12967-017-1328-z.
Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
Kawaguchi T, Foster B, Young J, Takabe K
J Mammary Gland Biol Neoplasia. 2017; 22(2):131-139.
PMID: 28451789
PMC: 5511343.
DOI: 10.1007/s10911-017-9378-7.
Modulation of Bax and mTOR for Cancer Therapeutics.
Li R, Ding C, Zhang J, Xie M, Park D, Ding Y
Cancer Res. 2017; 77(11):3001-3012.
PMID: 28381544
PMC: 5503158.
DOI: 10.1158/0008-5472.CAN-16-2356.
Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments.
Zarzosa P, Navarro N, Giralt I, Molist C, Almazan-Moga A, Vidal I
Clin Transl Oncol. 2016; 19(1):44-50.
PMID: 27718156
DOI: 10.1007/s12094-016-1557-2.
Modeling head and neck cancer stem cell-mediated tumorigenesis.
Pearson A, Jackson T, Nor J
Cell Mol Life Sci. 2016; 73(17):3279-89.
PMID: 27151511
PMC: 5312795.
DOI: 10.1007/s00018-016-2226-x.
Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts.
Bhadury J, Einarsdottir B, Podraza A, Olofsson Bagge R, Stierner U, Ny L
Oncotarget. 2016; 7(17):23801-11.
PMID: 27009863
PMC: 5029664.
DOI: 10.18632/oncotarget.8181.